Table 3.
Univariate analysis of risk factors for breast cancer death by age for women with stage I–III breast cancer diagnosed 1992–2005 (N = 1120)
| <35 years | 35–39 years | 40–49 years | 50–69 years | ||||
|---|---|---|---|---|---|---|---|
| n = 445 | n = 190 | n = 192 | n = 293 | ||||
| Unadjusted | 2.75 | (1.93–3.94) | 2.33 | (1.54–3.52) | 1.53 | (0.97–2.39) | |
| Year of diagnosis | |||||||
| 1992–1997 | 2.18 | (1.31–3.63) | 2.04 | (1.16–3.59) | 1.28 | (0.70–2.35) | |
| 1998–2002 | 4.02 | (2.16–7.50) | 2.93 | (1.37–6.27) | 1.80 | (0.78–4.16) | |
| 2003–2005 | 1.90 | (0.79–4.54) | 1.33 | (0.45–3.95) | 1.17 | (0.37–3.68) | |
| Non screening detection | 1.80 | (1.17–2.78) | 1.54 | (0.95–2.49) | 1.16 | (0.69–1.96) | |
| Positive heredity | 1.47 | (0.84–2.58) | 1.41 | (0.73–2.73) | 1.15 | (0.56–2.35) | |
| Tumor size (mm) | |||||||
| ≤20 | 3.42 | (1.91–6.12) | 3.19 | (1.65–6.20) | 1.75 | (0.85–3.63) | |
| 21–50 | 1.60 | (0.93–2.76) | 1.49 | (0.79–2.78) | 1.24 | (0.65–2.37) | |
| ≥51 | 1.26 | (0.51–3.11) | 0.55 | (0.18–1.70) | 0.23 | (0.03–1.93) | |
| Lymph node status | |||||||
| Negative | 2.10 | (1.22–3.62) | 2.30 | (1.21–4.39) | 0.63 | (0.26–1.49) | |
| 1–3 nodes positive | 2.63 | (1.33–5.19) | 1.90 | (0.90–4.00) | 1.20 | (0.50–2.89) | |
| ≥4 nodes positive | 1.41 | (0.70–2.87) | 1.05 | (0.45–2.41) | 2.05 | (0.94–4.47) | |
| Stage | |||||||
| I | 3.07 | (1.41–6.68) | 3.75 | (1.58–8.90) | 1.24 | (0.44–3.48) | |
| IIa | 1.55 | (0.82–2.94) | 1.24 | (0.56–2.78) | 0.24 | (0.05–1.06) | |
| IIb | 1.71 | (0.71–4.08) | 1.20 | (0.45–3.15) | 0.83 | (0.29–2.39) | |
| III | 1.42 | (0.73–2.80) | 1.04 | (0.48–2.27) | 1.94 | (0.92–4.10) | |
| Grade | |||||||
| I–II | 3.25 | (1.81–5.81) | 2.38 | (1.18–4.81) | 1.64 | (0.80–3.36) | |
| III | 1.46 | (0.87–2.47) | 1.37 | (0.75–2.51) | 0.91 | (0.46–1.83) | |
| Estrogen receptor | |||||||
| Positive | 2.89 | (1.85–4.53) | 2.28 | (1.36–3.85) | 1.36 | (0.78–2.39) | |
| Negative | 1.91 | (1.03–3.52) | 1.85 | (0.91–3.73) | 1.59 | (0.73–3.49) | |
| Progesterone receptor | 1.00 (ref.) | ||||||
| Positive | 2.77 | (1.53–5.01) | 2.45 | (1.26–4.79) | 1.10 | (0.52–2.31) | |
| Negative | 2.37 | (1.51–3.73) | 2.04 | (1.20–3.48) | 1.91 | (1.07–3.41) | |
| Ki67 (%) | |||||||
| Low ≤20 | 3.15 | (1.49–6.67) | 1.33 | (0.46–3.82) | 1.72 | (0.73–4.06) | |
| High ≥21 | 1.70 | (1.08–2.68) | 1.65 | (0.98–2.78) | 1.09 | (0.61–1.96) | |
| Her2 | |||||||
| Negative | 2.36 | (1.55–3.60) | 2.15 | (1.31–3.53) | 1.27 | (0.74–2.17) | |
| Positive | 1.45 | (0.56–3.74) | 0.78 | (0.25–2.46) | 1.38 | (0.42–4.52) | |
| Subtype | |||||||
| Luminal A | 1.84 | (0.49–6.86) | 0.55 | (0.06–4.67) | 0.29 | (0.03–2.44) | |
| Luminal B | 2.30 | (1.27–4.19) | 2.30 | (1.18–4.49) | 1.64 | (0.82–3.28) | |
| Luminal-Her2 | 0.84 | (0.23–3.02) | 0.75 | (0.18–3.16) | 0.75 | (0.13–4.50) | |
| Her2-positive | 1.77 | (0.41–7.67) | 0.56 | (0.08–3.98) | 2.20 | (0.40–12.03) | |
| Triple-negative | 1.26 | (0.61–2.61) | 1.35 | (0.57–3.21) | 1.09 | (0.39–3.07) | |
| Lymphovascular invasion | |||||||
| No | 2.66 | (1.74–4.06) | 2.12 | (1.29–3.49) | 1.14 | (0.64–2.01) | |
| Yes | 1.56 | (0.77–3.15) | 1.57 | (0.71–3.47) | 1.60 | (0.71–3.60) | |
| Invasive multifocality | |||||||
| No | 3.08 | (2.04–4.63) | 2.18 | (1.33–3.55) | 1.62 | (0.97–2.71) | |
| Yes | 1.76 | (0.84–3.71) | 2.26 | (1.00–5.12) | 1.12 | (0.43–2.91) | |
| Extensive DCIS | |||||||
| No | 3.82 | (1.93–7.54) | 4.03 | (1.89–8.62) | 1.93 | (0.85–4.41) | |
| Yes | 5.11 | (1.20–21.74) | 5.30 | (1.19–23.68) | 4.63 | (0.96–22.27) | |
| Locoregional recurrencea | |||||||
| No | 2.75 | (1.82–4.17) | 2.11 | (1.28–3.48) | 1.53 | (0.91–2.59) | |
| Yes | 1.44 | (0.71–2.94) | 1.50 | (0.69–3.27) | 0.96 | (0.40–2.31) | |
Hazard ratio (95 % confidence interval) for risk of breast cancer death according to age and one additional risk factor
Bold values indicate statistical significance at the p < 0.05 level
aLocoregional recurrence as first event